Almirall results: strong half driven by dermatology and Mexican sale sends shares soaring

26 July 2016
almirall-location-big-1

Spain's leading drugmaker Almirall (ALM: MC) has reported that its total revenue in the first half of 2016 was 428.1 million euros ($470.8 million), which is 5% higher than in the same period of 2015.

The announcement of the latest financial results on Tuesday sent Almirall’s share price soaring by 8% to 14.46 euros in afternoon trading.

Growth was driven by dermatology, sales in which have risen 13.3% since last year, and this therapy area now accounts for 43% of the company’s sales, compared to 41% in the first half of 2015.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical